The Latest Cardiac and Vascular News
Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory Clearances in the United Kingdom and United States Anticipated in Second Half of 2022 Preclinical Data Supporting Nomination […]
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced upsized underwritten public offering of 9,583,334 shares of its common stock at […]
CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its upsized underwritten public offering of 8,333,334 shares of its common stock at a public […]
Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with Potential Clearances for a UK Clinical Trial Application and US Investigational New Drug Application in Second Half of 2022 CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) […]
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. “Bo” Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company’s board of directors. “Bo […]
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash Equivalents and Marketable Securities […]
VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101 Clinical Formulation Led to Mean 68% Reduction in Plasma LDL-C in NHPs Out to One-Year with Good Tolerability; VERVE-101 Precursor Formulation Led to Durability of LDL-C […]
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st Annual Scientific Session & Expo CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new […]
Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight Novel Base Editing Approach and Proprietary Lipid Nanoparticle Delivery System Cash, Cash Equivalents and Marketable Securities of $360.4 Million with Cash Runway into 2024 CAMBRIDGE, Mass., […]
VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, […]
